Zhiyi Bio is a probiotics and living biopharmaceutical research and development company, dedicated to the research of micro-ecological innovative drugs NGPs (Next-generation probiotics, second-generation probiotics) and LBPs (Live biotherapeutics, living biological drugs) and therapeutic methods in the field of digestion and development. Recently, Zhiyi Biotech completed the B+ round of financing of 100 million yuan, which was invested by SDIC Venture Capital, Guangzhou Development Zone Fund, Heli Chuangxing Group, etc. The funds were mainly used to accelerate the clinical development of the company’s new drug pipeline.
This article is reproduced from: https://www.itjuzi.com/investevent/13318876
This site is for inclusion only, and the copyright belongs to the original author.